Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA11 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ITGA11 Products |
| Gene Delivery | ITGA11 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ITGA11 Products |
| Benchmark Ab | Anti-ITGA11 (Sequence of clinical benchmark) Recombinant positive control. |
View ITGA11 Products |
| Validator | ITGA11 siRNA Set For knockdown verification. |
View ITGA11 Products |
| Related Target A | ITGB1 Obligate heterodimerization partner required for functional integrin alpha-11/beta-1 collagen receptor signaling. |
View ITGB1 Products |
| Related Target B | FAP Co-expressed marker on cancer-associated fibroblasts (CAFs); ideal for combination therapy and stroma-targeting validation. |
View FAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter-screening (ITGA1, ITGA2, ITGA10) | Homolog panel proteins strictly verified by mass spectrometry to guarantee sequence identity and avoid off-target cross-reactivity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ITGA11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA11 therapeutics is intensifying, with major players shifting focus from traditional mAbs to stroma-targeting Antibody-Drug Conjugates (ADCs) and multi-specific integrin inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting cancer-associated fibroblast (CAF) depletion and the reversal of desmoplastic drug resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biotechs | Pancreatic Cancer, NSCLC, Triple-Negative Breast Cancer | Internalization Assay (Need high-purity ECD-Fc for conjugation and endocytosis screening) |
| Monoclonal Antibody (Blocking) | Fibrosis Specialists | Idiopathic Pulmonary Fibrosis (IPF), Liver Fibrosis | Ligand-Binding Inhibition Assay (Need stable ITGA11/ITGB1 heterodimer to block Collagen I binding) |
| Cell Therapy (CAR-T/CAR-NK) | Immunotherapy Developers | Solid Tumors (CAF microenvironment) | Target Cell Line Construction (Need high-titer Lentivirus for stable ITGA11 expression) |